A single institution retrospective study evaluating mitomycin dosing during chemoradiation in anal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed that aspirin use in patients with PIK3CA-mutated colorectal cancer reduced ...

Patient's tumor tissue (archival or fresh) is available to be sent to a central laboratory for PIK3CA testing. In case, tissue sample (archival or fresh) is not available or feasible, liquid biopsy ...